Download the Schwab app from iTunes®Close

Health Care Sector Rating: Outperform

The Health Care sector includes health care equipment and services (health care equipment and supplies, health care providers and services, and health care technology) and pharmaceuticals, biotechnology and life sciences tools and services.

Following the worst of the COVID-19 crisis, elective care has resumed, high expenses related to COVID-19 patient care have subsided, and medical equipment and pharmaceutical stocks have recovered. Meanwhile, the sector has many favorable long-term attributes, such as new cost-saving and care-improving advances in medical technologies, an aging global population, and a growing middle class in emerging-market economies—all of whom will demand more extensive drug treatments and medical care over time. Valuations are relatively attractive, and balance sheets in the sector are generally in good shape, increasing the possibility of higher dividend payments, share-enhancing stock buybacks, and mergers-and-acquisition (M&A) activity.

There are still risks, however. Any legislation to control drug prices or raise corporate taxes could weigh on pharmaceutical companies’ profits—although promising pipeline drugs can mitigate these risks. Additionally, the Supreme Court in June 2021 ruled that the individual mandate provision of the Affordable Care Act (ACA) was constitutional, thwarting efforts to repeal the entire ACA and avoiding potential sector upheaval.

Positives for the sector:

  • Strong balance sheets, with ample cash for dividends and M&A
  • Positive long-term demographics trends, including an aging global population and a growing middle class in emerging markets
  • Return in demand for elective procedures, drug sales, medical equipment and diagnostics
  • Valuations are attractive relative to the sector's historical average
  • Biotech and pharmaceuticals have strong drug development pipeline
  • Supreme Court rejected latest challenge to ACA

Negatives for the sector:

  • Extended-care facilities have seen a decline in enrollments and are likely to see higher costs related to virus mitigation requirements
  • Defensive sector during an economic expansion—though this was not an impediment in the previous cycle

Risks for the sector:

  • Prescription drug price controls and other regulations
  • Target of anti-competitive regulation
  • Surge in COVID-19 could reduce demand for elective medical care
  • New competition from Amazon Care, a hybrid telehealth/in-person health care offering

What do the ratings mean?

The sectors we analyze are from the widely recognized Global Industry Classification Standard (GICS®) groupings. After a review of risks and opportunities, we give each stock sector one of the following ratings:

  • Outperform: likely to perform better than the broader stock market*
  • Underperform: likely to perform worse than the broader stock market*
  • Neutral: no current view on likely relative performance

 

* As represented by the S&P 500 index

Want to learn more about a specific sector?  Click on a link below for more information or visit Schwab Sector Views to see how they compare. Clients can log in to see our top-rated stocks in the Health Care sector.

Communication Services Industrials
Consumer Discretionary Information Technology
Consumer Staples Materials
Energy Real Estate
Financials Utilities

 

What You Can Do Next

 

Important Disclosures

Schwab Sector Views do not represent a personalized recommendation of a particular investment strategy to you. You should not buy or sell an investment without first considering whether it is appropriate for you and your portfolio. Additionally, you should review and consider any recent market news.

All expressions of opinion are subject to change without notice in reaction to shifting market conditions. Data contained herein from third-party providers is obtained from what are considered reliable sources. However, its accuracy, completeness or reliability cannot be guaranteed. Supporting documentation for any claims or statistical information is available upon request.

Forecasts contained herein are for illustrative purposes only, may be based upon proprietary research and are developed through analysis of historical public data.

Past performance is no guarantee of future results and the opinions presented cannot be viewed as an indicator of future performance.

Investing involves risk including loss of principal.

Indexes are unmanaged, do not incur management fees, costs and expenses and cannot be invested in directly. For more information on indexes please see www.schwab.com/indexdefinitions.

The policy analysis provided by the Charles Schwab and Co., Inc., does not constitute and should not be interpreted as an endorsement of any political party.

All corporate names are for illustrative purposes only and are not a recommendation, offer to sell, or a solicitation of an offer to buy any security.

The Schwab Center for Financial Research (SCFR) is a division of Charles Schwab & Co., Inc.

(1121-1FH0)

Thumbs up / down votes are submitted voluntarily by readers and are not meant to suggest the future performance or suitability of any account type, product or service for any particular reader and may not be representative of the experience of other readers. When displayed, thumbs up / down vote counts represent whether people found the content helpful or not helpful and are not intended as a testimonial. Any written feedback or comments collected on this page will not be published. Charles Schwab & Co., Inc. may in its sole discretion re-set the vote count to zero, remove votes appearing to be generated by robots or scripts, or remove the modules used to collect feedback and votes.